Revascularization Strategies in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome (NSTE-ACS) and Severe Coronary Artery Disease (MILESTONE)

Multivessel and Left Main Coronary Artery Stenting in Comparison With Surgical Revascularization in Patients With Non ST Elevation Acute Coronary Syndrome. Prospective, Clinical Randomized Trial (The MILESTONE Trial)

MILESTONE STUDY is dedicated to problems connected with patients with multivessel coronary artery disease and/or with left main narrowing who present symptoms of acute ischemia. For such kind of patients according to current ACC/AHA guidelines CABG (surgical revascularization) is recommended as a treatment method. In comparison with CABG, recent studies have shown that PCI (percutaneous coronary intervention) is associated with a lower rate of periprocedural adverse events and similar long term event-free survival in patients with left main disease. Our latest non randomized registry and randomized LEMANS study, comparing LMCA (left main coronary artery) stenting with CABG confirmed above findings. LEMANS ACS (acute coronary syndrome) retrospective registry of patients with UPLMCA (unprotected LMCA) disease and non ST elevation ACS showed lower 30 day and trend toward lower one year mortality after PCI when compared with CABG. It should be stressed, that acute ischemia substantially increase the risk of CABG. In fact, there are limited data on the outcome of ULMCA stenting or CABG in patients with acute coronary syndromes (ACS).

Similarly, all randomized studies comparing PCI vs CABG in multivessel disease included mainly patients with stable angina, small cohort of patients with unstable angina and they excluded patients with non ST elevation Myocardial infarction.

In the SYNTAX study -largest PCI vs CABG trial, randomized patients were patients with low perioperative risk (logistic EUROSCORE <5) and ACS patients routinely excluded. High perioperative risk patients were included only in PCI registry.

Study Overview

• Status: Not yet recruiting
• Conditions: Acute Coronary Syndrome; Multivessel Coronary Artery Disease
• Intervention / Treatment: Procedure: PCI; Procedure: CABG

Detailed Description

Within last decade, aging of the population and coexistence of multiple comorbidities influenced a risk of patients presenting with acute coronary syndrome (ACS) 10,11. Furthermore, a steady decline in ST elevation ACS incidence and increase in non-ST elevation acute coronary syndrome (NSTE-ACS) has been observed 10,12,13, associated with poorer long term prognosis 14,15. This is related to the complexity of coronary artery disease in patients with NSTE-ACS, as nearly half of them have multivessel disease (MVD) 15. The optimal revascularization strategy in this group of patients remains unknown. Due to clinical presentation in most of cases early or delayed invasive strategy is preferred by both American and European guidelines 16,17, however the method of revascularization is not specified. Due to high surgical risk presentation, immediate stenting of the culprit lesion and delayed complete percutaneous revascularization is becoming a common practice. On the other hand, basing on the anatomical criteria coronary artery bypass grafting (CABG) should be the standard of care 18. Very few reports addressed so far the problem of optimal revascularization strategy in patients presenting with MVD and NSTE-ACS. A hypothesis of a positive outcome can be derived from some previous studies comparing PCI and CABG in which most of patients enrolled presented with NSTE-ACS 7-9,19, including our experience.

Aim and hypothesis:

Hence, the purpose of this study will be to compare contemporary coronary angioplasty with coronary artery bypass grafting in a prospective, clinical, multicenter, randomized trial. The hypothesis of this study is the non-inferiority of PCI compared to CABG in terms of the primary composite endpoint (death, myocardial infarction, stroke).

Method:

Patients with multivessel coronary artery disease, left main and acute coronary syndrome without ST segment elevation, qualified for early invasive treatment, with a Syntax Score below 33, and in whom the invasive cardiologist and cardiac surgeon will recognize both PCI and CABG as possible to achieve complete revascularization will be enrolled to the study. In the case of centers without the Cardiac Surgery Department, "Heart Team" consultations will take place via videoconference, and records of coronarography and echocardiography will be shared via the TeleDICOM system. The main exclusion criteria will be the qualification for conservative treatment, surgery other than CABG due to structural heart defect, ST segment elevation myocardial infarction, stable coronary artery disease, immediate need for PCI. After fulfilling the inclusion criteria and lack of exclusion criteria, the patient will be randomized in a 1: 1 ratio to either PCI or CABG. The PCI procedure will be performed after assessing the hemodynamic significance of all lesions with vFFR, FFR or iFR or using the latest generation drug eluting stents, and the implantation will be optimized based on intravascular imaging. CABG procedures will be performed based on the experience of the respective center, including the OPCAB technique, and the internal mammary artery will be used in each case. The primary endpoint of the study will be all cause death, myocardial infarction, and stroke in one-year follow-up. To prove the assumed hypothesis of the study, with the test power of 80% alpha error 5% and the percentage of lost to follow-up at the level of 5%, the study should include 500 patients in each group. Secondary endpoints will be ischemia driven revascularization, left ventricular ejection fraction, major and minor bleeding incidence, new onset of atrial fibrillation, de novo heart failure, unscheduled re-hospitalization, quality of life, and cost effectiveness. After the hospitalization, patients will be subjected to strict secondary prevention principles, including cardiac and cardiac surgery rehabilitation, and will undergo four specialistic follow-up visits with cardiac echo and stress tests at selected time points.

Anticipated outcomes:

In the case of positive results of the study, the efficacy and safety of PCI in the studied group of patients will be confirmed. This will contribute to the creation of a new guidelines in a given area, translating into faster and easier access to rapid invasive treatment. It will also facilitate the decision-making process in centers without cardiac surgery.

• Study Type: Interventional
• Enrollment (Anticipated): 1000
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Agata Krauze, PhD; Phone Number: +48885805002; Email: agata.krauze@ahop.pl

Study Locations

• Poland
  • Białystok, Poland
    • Clinical University Hospital
    • Contact: Sławomir Dobrzycki, Prog, MD,PhD
  • Katowice, Poland
    • Upper Silesian Heart Center of Medical Univeristy of Silesia
    • Contact: Wojciech Wojakowski, Prof. MD, PhD
  • Malopolska
    • Chrzanow, Malopolska, Poland, 32-500
      • American Heart of Poland, Malopolska Centre for Heart and Vascular Disease
      • Contact: Iwona Banasiewicz-Szkrobka, MD, PhD; Phone Number: 0048602457602; Email: wilenka@wp.pl
      • Principal Investigator: Iwona Banasiewicz-Szkrobka, MD, PhD
      • Sub-Investigator: Aleksander Zurakowski, MD,PhD
  • Silesia
    • Bielsko-Biala, Silesia, Poland, 43-316
      • American Heart of Poland, 2-nd Department of Cardiology
      • Contact: Bogdan Gorycki, MD,PhD; Phone Number: (+48) (33) 829 08 63; (33) 810
      • Principal Investigator: Bogdan Gorycki, MD,PhD
    • Dabrowa Gornicza, Silesia, Poland, 41-300
      • American Heart of Poland,3-rd Depatment of Invasive Cardiology, Angiology and Electrophysiology
      • Contact: Marek Kondys, MD,PhD; Phone Number: (+48) (33) 829 08 63; (33) 810
      • Principal Investigator: Marek Kondys, MD,PhD
      • Sub-Investigator: Marcin Debinski, MD,PhD
    • Ustron, Silesia, Poland, 43-450
      • American Heart of Poland 1-st Department of Cardiology and Angiology
      • Contact: Marek Krol, MD,PhD; Phone Number: (+48) (33) 854 58 57, (33) 854; Email: m.krol@klinikiserca.pl
      • Principal Investigator: Marek Krol, MD,PhD
    • Zabrze, Silesia, Poland, 41-800
      • Silesian Centre for Heart Disease, Department of Cardiosurgery and Transplantation
      • Contact: Mariusz Gasior, Prof; Phone Number: 004832 273 26 81
      • Principal Investigator: Marian Zembala, Prof.
      • Principal Investigator: Mariusz Gasior, Prof

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 19 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Acute Coronary Syndrome without ST elevation (NSTE-ACS): Unstable Angina (Braunwald's class IB,IC,IIB,IIC,IIIB,IIIC) or Non ST Elevation Myocardial Infarction (NSTEMI) requiring prompt revascularization (within 72 hours)
• Two vessel disease with proximal LAD stenosis or three vessel disease
• Unprotected Left Main Coronary Artery (ULMCA) de novo disease with or without concomitant single or multivessel coronary artery disease
• Syntax Score =<33
• Patient eligible both for CABG and PCI, confirmed by interventional cardiologist and surgeon offering similar extension of revascularisation
• Signed informed consent

Exclusion Criteria:

• age <21
• ST Elevation Myocardial Infarction;
• Stable angina;
• Patients in Killip IV class;
• Patients required immediate PCI procedure (e.g. electric instability);
• Patients unable to tolerate, obtain or comply with dual antiplatelet therapy for at least 1 year
• History of haemorrhagic stroke within a year before procedure
• Ischemic stroke or TIA within past 6 weeks.
• End Stage Chronic renal insufficiency requiring dialysis
• Concomitant structural or valve disease requiring cardiac surgery
• Prior PCI of left main trunk one year prior to randomization
• Prior PCI of any other coronary artery lesion within 1 year prior to randomization
• Prior CABG at any time prior to randomization
• Need for any concomitant cardiac surgery other than CABG (e.g. valve surgery, aortic repair, etc.), or intent that if the patient will be randomized to surgery, any cardiac surgical procedure other than isolated CABG will be performed
• Patients requiring additional surgery (cardiac or non cardiac) within 1 year
• Pregnancy or intention to become pregnant (women of child bearing age must have a recent negative pregnancy test prior to randomization)
• Non cardiac co-morbidities with life expectancy less than 3 years

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: PCI with DES implantation; Percutaneous Coronary Intervention Implantation of Drug-Eluting Stents	Procedure: PCI; Percutaneous Coronary Intervention with contemporary drug eluting stent, fractional flow reserve or iFR measurement and optimisation with intravascular imaging; Other Names: •Percutaneous coronary intervention; •Multivessel coronary disease; •Left main narrowing
Active Comparator: CABG; Coronary Artery Bypass Grafting.On-pump or Off-pump CABG	Procedure: CABG; Coronary Artery Bypass Graft; Other Names: Multivessel coronary artery disease; Coronary artery bypass graft; Left Main narrowing

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
MACCE - Major Adverse Cardiac and Cerebral Events	The primary endpoint is a composite of all cause death, revascularization procedure: PCI or CABG. The hypothesis test is designed to show non-inferiority of PCI to CABG for the primary endpoint	One year after revascularization procedure

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
SAE - Serious Adverse Events	ischemia driven revascularization, left ventricular ejection fraction, major and minor bleeding incidence, new onset of atrial fibrillation, de novo heart failure, unscheduled re-hospitalization	peri-hospital period, one month and one year and two years after revascularization procedure
Procedural and post procedural complication	Procedural and post procedural complication: length of hospital stay and frequency of prolonged hospitalization ; return to work; readmissions and cause of readmissions; angina and functional status; medications.	peri-hospital period, one month and one year after revascularization procedure
Overall costs of treatment strategies.	Hospital costs and long-term cost-effectiveness.	one year ofter revascularization procedure
Occurence of stent thrombosis or graft occlusion	Stent trombosis will be defined in accordance with ARC definition.	peri-hospital period, one month and one year after revascularization procedure
Hemorrhagic complications.	Hemorrhagic complications will be clasified according to TIMI scale.	peri-hospital period, one month and one year after revascularization procedure
Frequency and impact of complete revascularization	Complete revascularization will be defined on an anatomic basis and by revascularization of all significant ischemic areas.	one year after revascularization procedure
LVEF	Left Ventricle Ejection Fraction	6 and 12 months

Collaborators and Investigators

• Sponsor: American Heart of Poland
• Collaborators: Silesian Centre for Heart Diseases; Andrzej Frycz Modrzewski Kraków University, Kraków, Poland; Upper Silesian Heart Center of Medical University of Silesia, Katowice, Poland; Clinical University Hospital, Białystok, Poland
• Investigators: Principal Investigator: Piotr P Buszman, MD,PhD, Assoc. Prof, American Heart of Poland; Principal Investigator: Andrzej Bochenek, Prof, MD,PhD, American Heart of Poland

Publications and helpful links

General Publications

• Buszman PE, Kiesz SR, Bochenek A, Peszek-Przybyla E, Szkrobka I, Debinski M, Bialkowska B, Dudek D, Gruszka A, Zurakowski A, Milewski K, Wilczynski M, Rzeszutko L, Buszman P, Szymszal J, Martin JL, Tendera M. Acute and late outcomes of unprotected left main stenting in comparison with surgical revascularization. J Am Coll Cardiol. 2008 Feb 5;51(5):538-45. doi: 10.1016/j.jacc.2007.09.054.
• Buszman PP, Bochenek A, Konkolewska M, Trela B, Kiesz RS, Wilczynski M, Cisowski M, Krejca M, Banasiewicz-Szkrobka I, Krol M, Kondys M, Wiernek S, Orlik B, Martin JL, Tendera M, Buszman PE. Early and long-term outcomes after surgical and percutaneous myocardial revascularization in patients with non-ST-elevation acute coronary syndromes and unprotected left main disease. J Invasive Cardiol. 2009 Nov;21(11):564-9.
• Buszman PE, Buszman PP, Kiesz RS, Bochenek A, Trela B, Konkolewska M, Wallace-Bradley D, Wilczynski M, Banasiewicz-Szkrobka I, Peszek-Przybyla E, Krol M, Kondys M, Milewski K, Wiernek S, Debinski M, Zurakowski A, Martin JL, Tendera M. Early and long-term results of unprotected left main coronary artery stenting: the LE MANS (Left Main Coronary Artery Stenting) registry. J Am Coll Cardiol. 2009 Oct 13;54(16):1500-11. doi: 10.1016/j.jacc.2009.07.007. Epub 2009 Aug 21.
• Park DW, Seung KB, Kim YH, Lee JY, Kim WJ, Kang SJ, Lee SW, Lee CW, Park SW, Yun SC, Gwon HC, Jeong MH, Jang YS, Kim HS, Kim PJ, Seong IW, Park HS, Ahn T, Chae IH, Tahk SJ, Chung WS, Park SJ. Long-term safety and efficacy of stenting versus coronary artery bypass grafting for unprotected left main coronary artery disease: 5-year results from the MAIN-COMPARE (Revascularization for Unprotected Left Main Coronary Artery Stenosis: Comparison of Percutaneous Coronary Angioplasty Versus Surgical Revascularization) registry. J Am Coll Cardiol. 2010 Jul 6;56(2):117-24. doi: 10.1016/j.jacc.2010.04.004. Epub 2010 May 6.
• Park DW, Kim YH, Yun SC, Lee JY, Kim WJ, Kang SJ, Lee SW, Lee CW, Kim JJ, Choo SJ, Chung CH, Lee JW, Park SW, Park SJ. Long-term outcomes after stenting versus coronary artery bypass grafting for unprotected left main coronary artery disease: 10-year results of bare-metal stents and 5-year results of drug-eluting stents from the ASAN-MAIN (ASAN Medical Center-Left MAIN Revascularization) Registry. J Am Coll Cardiol. 2010 Oct 19;56(17):1366-75. doi: 10.1016/j.jacc.2010.03.097.

Study record dates

Study Major Dates

• Study Start (Anticipated): January 1, 2021
• Primary Completion (Anticipated): January 1, 2025
• Study Completion (Anticipated): June 1, 2025

Study Registration Dates

• First Submitted: March 8, 2011
• First Submitted That Met QC Criteria: March 8, 2011
• First Posted (Estimate): March 9, 2011

Study Record Updates

• Last Update Posted (Actual): May 1, 2020
• Last Update Submitted That Met QC Criteria: April 29, 2020
• Last Verified: April 1, 2020

More Information

Terms related to this study

• Keywords: Percutaneous Coronary Intervention; Fractional Flow Reserve; Coronary Artery Bypass Grafting; Drug-Eluting Stent; Multivessel Coronary Artery Disease; Left Main Narrowing; Instant wave-free ratio; virtual Fractional Flow Reserve
• Additional Relevant MeSH Terms: Pathologic Processes; Heart Diseases; Cardiovascular Diseases; Vascular Diseases; Arteriosclerosis; Arterial Occlusive Diseases; Disease; Coronary Artery Disease; Myocardial Ischemia; Coronary Disease; Syndrome; Acute Coronary Syndrome
• Other Study ID Numbers: AHP-1

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No